Lepu Medical released its 2026 half-year report. Net profit attributable to the parent in the first half was 499 million yuan, down 27.7% year on year. Operating revenue was 3.21 billion yuan, down 4.6% year on year. Net profit attributable to the parent after deducting non-recurring items was 481 million yuan, down 27.4% year on year. Net operating cash flow was 633 million yuan, down 0.6% year on year. Second-quarter operating revenue was 1.54 billion yuan, down 5.6% year on year, and net profit attributable to the parent was 253 million yuan, down 19.1% year on year. The company said volume-based procurement policies have had a significant impact on medical consumables and generic drugs. It is actively expanding self-pay consumer healthcare products, gradually reducing investment in generic drugs, and focusing on innovative drugs in the cardiovascular field.
Lepu Medical Tech BeijingNet profit down 27.7% and revenue down 4.6% in H1, with continued decline in Q2.
